文献速递免疫规划卫生政策与健康促进

合理设计的鞭毛蛋白-L2融合蛋白诱导针对多型HPV的血清和黏膜中和抗体

A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types.
PubMed 文献 · Vaccine · 2019-06-15

本研究构建了含HPV18/33/58/59 RG-1表位及16L2 aa.11-88肽的L2串联体,与鞭毛蛋白融合形成Fla-5PcL2,并在小鼠中评估免疫原性。皮下免疫诱导强效血清中和抗体,鼻内免疫诱导黏膜IgA和交叉中和抗体,并完全保护阴道HPV攻击。

要点

  • Fla-5PcL2在大肠杆菌中高产稳定表达。
  • 皮下免疫诱导针对不同HPV型的强血清中和抗体。
  • 鼻内免疫诱导黏膜IgA和交叉中和抗体,完全保护阴道攻击。

核心结论

  • Fla-5PcL2是有前景的候选疫苗,可能满足低资源地区需求。

研究设计与样本

  • 构建L2串联体与鞭毛蛋白融合蛋白Fla-5PcL2,在E. coli表达,小鼠模型经系统(皮下)和黏膜(鼻内)途径评估免疫原性。

主要发现

  • 皮下免疫Fla-5PcL2诱导针对不同HPV型的强血清中和抗体。
  • 鼻内免疫Fla-5PcL2诱导黏膜分泌物中显著L2特异性IgA和交叉中和抗体,血清中中等滴度交叉中和抗体。
  • Fla-5PcL2诱导对阴道HPV攻击的完全保护。

临床怎么用

  • 鼻内无针免疫可能提高疫苗依从性并减少公共卫生资源需求。
  • 黏膜抗体在感染部位提供一线防御,支持黏膜免疫策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The amino terminus of human papillomavirus (HPV) minor capsid protein L2 harbors several conserved neutralizing epitopes, including aa.17-36 (RG-1 epitope) and aa.65-85 consensus epitope (cL2 epitope), which are considered to be promising for the construction of cost-effective pan-HPV vaccine candidates. However, the immunogenicity of L2 epitope/peptide is rather weak, and the neutralizing spectrum induced by single type of L2 antigen is suboptimal. In this study, we constructed L2 concatemer with HPV18/33/58/59 RG-1 epitopes and 16L2 aa.11-88 peptide, and fused it with flagellin, a strong systemic and mucosal adjuvant, by hypervariable region replacement. A copy of cL2 epitope was also introduced to the C-terminus of the recombinant protein. The resultant Fla-5PcL2 protein can be produced in E. coli expression system with high yield and good stability. We assessed the immunogenicity of Fla-5PcL2 in mouse model via systemic and mucosal route, and found that subcutaneous immunization with Fla-5PcL2 induced robust serum neutralizing antibodies against divergent HPV types, while intranasal immunization with Fla-5PcL2 induced remarkable L2-specific IgA and cross-neutralizing antibodies in mucosal secretions, and medium titers of cross-neutralizing antibodies in sera. Moreover, Fla-5PcL2 induced full protection against vaginal HPV challenges. As mucosal antibodies provide the first-line defense at infection sites, and needle-free immunizations may increase vaccine compliance and require less public health resources, our results demonstrate that Fla-5PcL2 is a promising vaccine candidate which possibly meet the need in low-resource regions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhang T, Chen X, Liu H, et al. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types. Vaccine. 2019. PMID: 31213378. doi:10.1016/j.vaccine.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。